Fig 1: Apelin relived early inflammatory response in heart of diabetic mice. (A) Representative images of immunohistochemistry for CD68, mac-2 and E-cadherin in heart sections from C57 and diabetic mice with or without apelin/F13A treatment as quantified in (B, C and D) (CD68: diabetes (P = 0.001), treatment (P = 0.000), interaction (P = 0.578); mac-2: diabetes (P = 0.263), treatment (P = 0.002), interaction (P = 0.054); E-cadherin diabetes (P = 0.000), treatment (P = 0.000), interaction (P = 0.000); n = 6 mice per group, *P < 0.05). Scale bars represent 50 μm.
Fig 2: Suppressive effects of prostaglandin E synthase (PTGES) siRNA in IFN-γ-treated MSCs on the phenotypic change of macrophages from M1 to M2. (a) THP-1 monocytes were stimulated by PMA for 48 h and then incubated with CM from IFN-γ-treated hMSCs transfected with negative control (NC) siRNA or PTGES siRNA. After 48 h, the cells were collected and subjected to western blot analysis of CD163 and CD68. CD163 protein levels were normalized to GAPDH and CD68 levels (n = 5 in each group). The blots are the cropped images from different parts of the same gel. Full-length gel images are provided in the supplementary file. The samples derive from the same experiment and that gels were processed in parallel. Data are presented as the mean ± SD. *p < 0.05, **p < 0.01.
Fig 3: Effect of Phenacetinum 4CH on ex vivo necrosis, CD31, CD163, and CD68 expression. Photographs 4A and 4C show representative tumor sections from control or Phenacetinum 4CH treated mice. (A) HPS staining of tumor sections (left panel: control, right panel: Phenacetinum 4CH) showing tumor necrosis (area delimited by continuous line). (B) Semi-quantitative analysis with Image J software of necrosis area (% of total surface). (C) IHC staining in control tumor (left column) and Phenacetinum-treated tumor (right column) using anti-CD31, CD163, and CD68 antibodies. (D) Semi-quantitative with image J software analysis of CD31 staining (% of total surface) and expression of CD163+ and CD68+ cells (number/10 High-Power Fields). Data are expressed as the mean +/- SEM (*p < 0.05, **p < 0.01).
Fig 4: Late-in-life glial activation is evident in the HC after young adult CSS. (A) Confocal images of HC at Bregma AP −2.18 mm showing Iba-1 (488, green, left panels), CD68 (488, green, middle panels), and GFAP (594, red, right panels) labeling in mice 1 year after CSS (lower panels) and Rest (upper panels) exposures. (B) Percentage area in CA1 for Iba-1, CD68 and GFAP across Rest (black bars) and CSS conditions (blue bars). (C) Percent increase (relative to Rest) in CSS-exposed mice in the area covered for Aβ and glial markers (Iba-1, CD68 and GFAP), comparing CA1 (dark blue) and CA3 (blue/white striped). (D) Percentage of Iba-1-labeled microglia with dystrophic features in CA1 and CA3 in CSS-exposed mice. (E) High power confocal images of Iba-1-labeled (red) microglia with DAPI (blue) labeled nuclei in Rest (left panel) and CSS (middle and right panels) mice reveal dramatic changes in morphology of microglia. Arrow highlights an amoeboid microglial cell (middle panel) and arrow heads reveal vacuolar changes in CSS microglia (right panel). CC, corpus callosum; Or, oriens layer, SR, stratum radiatum; ML, moleculare lacanosum, DG, dentate gyrus. Data are mean ± SE and were analyzed in B, D by one-way ANOVA using Sidak’s post hoc comparisons for sleep condition effects and in C by two-way ANOVA with selected post-hoc Tukey analyses for region. *p < 0.05, ***p < 0.001; ****p < 0.0001. Calibration bars, A, 200 µm, C, 25 µm.
Fig 5: CEL-PRNPs reduce the number of OCs and inflammatory macrophages in joints of rats with advanced arthritis.a TUNEL immunofluorescence staining in ankle joints from AIA rats receiving the indicated treatment (Scale bar = 200 μm) (n = 5 independent animals). b Immunohistochemical analyses of the TRAP-stained OCs and CD68-stained synovial macrophages in the joint tissues from rats receiving the indicated treatment (Scale bar = 100 μm) (n = 5 independent animals). c RANKL/OPG ratio in arthritic joints, IL-1β secretion in blood, and TNF secretion in blood from rats receiving the indicated treatment. Data represent mean ± SD (n = 5 independent animals). Statistical significance was determined by a two-sided Student’s t test. d Detection of IL-1β, TNF, OCN, and ALP expression levels in arthritic joints in different groups. Arthritic joints in different groups were stained with IL-1β, TNF, and OCN antibodies, respectively. ALP was stained light–dark in arthritic joints from different groups (Scale bar = 100 μm) (n = 5 independent animals). CEL celastrol CEL-NPs CEL-loaded poly (d, l-lactide-co-glycolide) (PLGA) nanoparticles, CEL-RNPs CEL-loaded RGD peptide-modified PLGA nanoparticles, CEL-PRNPs CEL-loaded matrix metalloproteinase 9 (MMP9)-cleavable polyethylene glycol (PEG)- and RGD peptide-modified PLGA nanoparticles, TUNEL TdT-mediated dUTP nick end labeling, TRAP tartrate-resistant acid phosphatase, RANKL receptor of activator of NF-kB ligand, OPG osteoprotegerin, IL-1β interleukin-1 β, TNF tumor necrosis factor, OCN osteocalcin, ALP alkaline phosphatase.
Supplier Page from Abcam for Anti-CD68 antibody